CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
快速演进的免疫治疗在慢性活动性 Epstein-Barr 病毒病中的作用
英文原题：Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.
查看英文原题
Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
慢性活动性EB病毒（CAEBV）病是一种EB病毒相关T/NK细胞淋巴增殖性疾病。目前仍缺乏治疗该病的标准方案，但基本治疗原则包括控制炎症反应、抑制肿瘤增殖和重建免疫功能。造血干细胞移植目前是唯一可治愈该病的方法。近年来，免疫治疗快速发展，并广泛用于多种血液系统恶性肿瘤。包括PD-1抑制剂在内的多种免疫治疗药物也已显示治疗CAEBV的安全性和疗效；EB病毒特异性T细胞等免疫细胞疗法也展示出其在CAEBV治疗中的独特优势。
展开英文摘要原文
Chronic active Epstein-Barr Virus disease is a kind of Epstein-Barr Virus associated T/NK cell lymphoproliferative disease. At present, there is still a lack of standard therapeutic regimen for its treatment, but its basic treatment principles include controlling inflammatory response, anti-tumor proliferation, and immune reconstitution. Hematopoietic stem cell transplantation is currently the only method that can cure this disease.
In recent years, immunotherapy has developed rapidly and is widely used in the treatment of various hematological malignancies; various immunotherapy drugs, including PD-1 inhibitors, have also demonstrated their safety and efficacy in CAEBV, while immune cell therapies such as Epstein- Barr virus-specific T cells have also displayed their unique advantages in CAEBV.
论文信息
- 作者
- Yan S、Ming X、Zhu X、Xiao Y
- 单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39691713 · DOI 10.3389/fimmu.2024.1451977
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →